Kymera Therapeutics Inc (NASDAQ: KYMR) open the trading on Wednesday, with great promise as it jumped 5.50% to $35.10, before settling in for the price of $33.27 at the close. Taking a more long-term approach, KYMR posted a 52-week range of $29.07-$53.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 233.20%. Meanwhile, its Annual Earning per share during the time was -26.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -20.69%. This publicly-traded company’s shares outstanding now amounts to $64.89 million, simultaneously with a float of $53.96 million. The organization now has a market capitalization sitting at $2.28 billion. At the time of writing, stock’s 50-day Moving Average stood at $37.76, while the 200-day Moving Average is $41.49.
Kymera Therapeutics Inc (KYMR) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Kymera Therapeutics Inc’s current insider ownership accounts for 16.91%, in contrast to 95.08% institutional ownership. According to the most recent insider trade that took place on Mar 03 ’25, this organization’s Chief Legal Officer sold 2,241 shares at the rate of 30.45, making the entire transaction reach 68,239 in total value, affecting insider ownership by 80,085. Preceding that transaction, on Mar 03 ’25, Company’s Chief Operating Officer sold 1,383 for 30.45, making the whole transaction’s value amount to 42,113. This particular insider is now the holder of 67,800 in total.
Kymera Therapeutics Inc (KYMR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
Kymera Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -20.69% and is forecasted to reach -4.03 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -10.79% through the next 5 years, which can be compared against the -26.36% growth it accomplished over the previous five years trading on the market.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Let’s observe the current performance indicators for Kymera Therapeutics Inc (KYMR). It’s Quick Ratio in the last reported quarter now stands at 7.53. The Stock has managed to achieve an average true range (ATR) of 2.16. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 48.43.
In the same vein, KYMR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.97, a figure that is expected to reach -0.89 in the next quarter, and analysts are predicting that it will be -4.03 at the market close of one year from today.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
[Kymera Therapeutics Inc, KYMR] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 73.29% While, its Average True Range was 2.12.
Raw Stochastic average of Kymera Therapeutics Inc (KYMR) in the period of the previous 100 days is set at 24.96%, which indicates a major fall in contrast to 61.34% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 78.80% that was higher than 60.84% volatility it exhibited in the past 100-days period.
